Response to immune-based augmentation treatment for depression: a potential role of immunosenescence
Abstract
= 0.055, respectively). Our results indicate that response to celecoxib as an augmentation treatment for depression can be age-dependent, with younger patients responding better to treatment. In addition, immunological cell type profiles at baseline differ between both age groups, supporting the hypothesis that changes in treatment efficacy might follow from immunological changes that happen during aging. Our result fits with the growing body of literature focusing on immunosenescence and that aging of the immune system is relevant for treatment response and personalized treatment choices. Replication in an independent sample is needed to confirm the role of age in immune-focused treatment strategies for depression.
Fields of Study & Subjects
Tryptophan and brain disorders
Treatment of Major Depression
Stress Responses and Cortisol
Publication details
- Journal / source
- Neuroscience Applied
- Publisher
- Elsevier BV
- Volume
- 5
- Pages
- 106986–106986
- Publication date
- 1 January 2026
- Language
- EN